Mediterr J Rheumatol 2018;29(1):56-8
Role of miR200b-5p miRNA in lymphomagenesis associated with Sjögren’s syndrome (SS)
Authors Information

Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Greece

  1. Tzioufas A G, Kapsogeorgou E K, Moutsopoulos H M. Pathogenesis of Sjogren's syndrome: what we know and what we should learn. J Autoimmun 2012;39:4-8.
  2. Voulgarelis M, Dafni U G, Isenberg D A, Moutsopoulos H M. Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome. Arthritis Rheum 1999;42:1765-72.
  3. Skopouli F N, Dafni U, Ioannidis J P, Moutsopoulos H M. Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin Arthritis Rheum  2000;29:296-304.
  4. Theander E, Manthorpe R, Jacobsson L T. Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study. Arthritis Rheum 2004;50:1262-9.
  5. Papageorgiou A, Ziogas D C, Mavragani C P, et al. Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients. PloS one 2015;10(2):e0116189.
  6. Ioannidis J P, Vassiliou V A, Moutsopoulos H M. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 2002;46:741-7.
  7. Kassan S S, Thomas T L, Moutsopoulos H M, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978;89:888-92.
  8. Zintzaras E, Voulgarelis M, Moutsopoulos H M. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337-44.
  9. Baimpa E, Dahabreh I J, Voulgarelis M, Moutsopoulos H M. Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine 2009;88:284-93.
  10. Brito-Zeron P, Ramos-Casals M, Bove A, Sentis J, Font J. Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors. Rheumatology 2007;46:1359-62.
  11. Christodoulou M I, Kapsogeorgou E K, Moutsopoulos H M. Characteristics of the minor salivary gland infiltrates in Sjogren's syndrome. J Autoimmun 2010;34:400-7.
  12. Gerli R, Muscat C, Giansanti M, et al. Quantitative assessment of salivary gland inflammatory infiltration in primary Sjogren's syndrome: its relationship to different demographic, clinical and serological features of the disorder. Br J Rheumatol 1997;36:969-75.
  13. Nocturne G, Virone A, Ng W F, et al. Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjogren's Syndrome. Arthritis Rheum 2016;68:977-85.
  14. Papageorgiou A, Voulgarelis M, Tzioufas A G. Clinical picture, outcome and predictive factors of lymphoma in Sjogren syndrome. Autoimmun Rev 2015;14:641-9.
  15. Theander E, Vasaitis L, Baecklund E, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. Ann Rheum Dis 2011;70:1363-8.
  16. Bombardieri M, Pitzalis C. Ectopic lymphoid neogenesis and lymphoid chemokines in Sjogren's syndrome: at the interplay between chronic inflammation, autoimmunity and lymphomagenesis. Curr Pharm Biotechnol 2012;13:1989-96.
  17. Bombardieri M, Barone F, Humby F, et al. Activation-induced cytidine deaminase expression in follicular dendritic cell networks and interfollicular large B cells supports functionality of ectopic lymphoid neogenesis in autoimmune sialoadenitis and MALT lymphoma in Sjogren's syndrome. J Immunol 2007;179:4929-38.
  18. Pitzalis C, Jones G W, Bombardieri M, Jones S A. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat Rev Immunol 2014;14:447-62.
  19. Kapsogeorgou E K, Tzioufas A G. Glandular epithelium: Innocent bystander or leading actor In: Roberto Gerli EB, Alessia Alunno, ed. Sjogren's Syndrome. Novel Insights in Pathogenic, Clinical and Therapeutic Aspects: Academic Press;2016:189-98.
  20. Moutsopoulos H M. Sjogren's syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 1994;72:162-5.
  21. Morva A, Kapsogeorgou E K, Konsta O D, Moutsopoulos H M, Tzioufas A G. Salivary Gland Epithelial Cells (Sgecs) Promote the Differentiation of B Cells. Ann Rheum Dis 2013;72:77.
  22. Gourzi V C, Kapsogeorgou E K, Kyriakidis N C, Tzioufas A G. Study of microRNAs (miRNAs) that are predicted to target the autoantigens Ro/SSA and La/SSB in primary Sjogren's Syndrome. Clin Exp Immunol 2015;182:14-22.
  23. Rhodes L V, Martin E C, Segar H C, et al. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer. Oncotarget Jun 30 2015;6:16638-52.
  24. Humphries B, Yang C. The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy. Oncotarget 2015;6:6472-98.
  25. Senfter D, Madlener S, Krupitza G, Mader R M. The microRNA-200 family: still much to discover. Biomol Concepts 2016;7:311-9.
  26. Huang W T, Kuo S H, Cheng A L, Lin C W. Inhibition of ZEB1 by miR-200 characterizes Helicobacter pylori-positive gastric diffuse large B-cell lymphoma with a less aggressive behavior. Mod Pathol 2014;27:1116-25.